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INTRODUCTION
Community and hospital acquired bacterial pneumonias are
associated with significant mortality and morbidity (1). It is
essential to achieve sufficiently high antibiotic exposure in
the epithelial lining fluid (ELF) in order to obtain sufficient
efficacy and to prevent selection for resistant or persistent bac-
terial subpopulations (2). However, antibiotic concentrations
in the ELF may be significantly different from concentration
in the plasma (3). Hence, the characterization of antibiotic
ELF concentrations is important for antibiotics aimed at
treating lung infections. Bronchoalveolar lavage (BAL) is most
commonly used to quantify antibiotic drug concentrations in
humans. However, the technique has significant limitations
including the limitation of a single sample per patient given
the invasiveness of obtaining the BAL sample (4), and the
significant variability between measurements. Approaches to
predict lung penetration of antibiotics are thus highly relevant
to support informative BAL study design and to support the
selection or prioritization of antibiotic candidates.
We previously developed a quantitative structure-
pharmacokinetic parameter relationship (QSPKR) model to
predict antibiotic lung penetration of several classes of anti-
infective agents (5). This model utilized a regularized elastic
net regression approach to relate multiple specific chemical
structural properties or descriptors to the ratio of the concen-
tration in the ELF to the unbound plasma concentration. The
model was trained based on log-transformed clinical ELF and
plasma concentration data from 56 unique anti-infective com-
pounds that were extracted from the previous publications of
clinical lung penetration studies. The model was validated
using a leave-one-out cross validation and by prediction of a
limited set of five anti-infective compounds not used for model
development. Since then several new clinical lung penetration
studies have been published. The aim of this report was to
perform a more extensive external validation of the published
model to further evaluate its predictive value.
METHODS
We searched the PubMed database and relevant microbiolo-
gy conference abstracts for clinical studies reporting anti-
infective ELF and plasma concentrations in humans between
year 2011 and 2017.We also included the five antibiotics used
for the original external validation. Antibiotics already present
in the training dataset used for the model development were
excluded. For each drug identified and included we extracted
the non-extrapolated mean AUCELF and AUCplasma values.
The AUCplasma values were converted to unbound concentra-
tions (fAUCplasma) using the reported protein binding values
obtained from the DrugBank database. The AUCELF-
fAUCplasma ratio was collected and subsequently log-
transformed to obtain the clinically observed log ELF/
plasma penetration ratio (EPR). Using an R script (included
as supplemental material in the original model publication),
we generated the same 145 chemical descriptors used for the
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developed QSPKR model using the R package Rcdk.
Subsequently, we applied the original elastic net regression
model, without any modifications, to predict the log EPR
values for each antibiotic included in the new validation data
set, which were compared with the clinically reported log
EPRs. This comparison was done by graphically assessing
the clinically reported log EPR versus the model predicted
log EPR values as well as reporting the percentage of the
predictions being outside a 3-fold change from the observa-
tions. Additionally we assessed the models capability to char-
acterize drugs ability to penetrate the lungs in a semi-
quantitative manner.
RESULTS
We identified nine anti-infective drugs for which EPRs could
be determined and which were not included in the original
model. Together with the five antibiotics (arbekacin,
GSK2251052, tedizolid, imipenem, peramivir) previously in-
cluded for the external validation in the original publication
the new validation dataset comprised of 14 compounds. The
studies for each of these 14 anti-infective agents are summa-
rized in Table I.
Themodel predictions for the 14 drugs were in line with the
predictive performance reported in the original publication
(Fig. 1), with a root mean squared error of 1.42. For 57%
(n=8/14) of the drugs the predicted EPRs were within a 3-
fold difference from the observations. The model predicted
under or over-exposure compared to plasma, i.e. EPR > 1
or EPR < 1 and log EPR > 0 or log EPR < 0 for un-
transformed and log-transformed EPR respectively, correctly
for 93% (n=13/14) of the drugs. A trend towards under-
prediction of the log EPR was observed, particularly for
eravacycline, temocillin, and tedizolid.
DISCUSSION
The external validation analysis of the previous developed
QSPKR lung penetration model has shown a predictive per-
formance in line with the reported prediction performance of
the original publication. In the current validation the number
of antibiotics outside a 3-fold prediction error for un-
transformed ERP was 43% whereas in the original publica-
tion it was 20% for the small external validation set and 39%
for the leave-one-cross validation analysis of the training
dataset. Notably, as no model development was performed
at this stage, no leave-one-cross validation analysis was con-
ducted and thus no comparable metric was obtained.
Three classes of anti-infective drugs were included in this
validation that were not used for the training of the original
model, i .e . the leucyl-tRNA synthetase inhibitor
GSK2251052, the non-beta-lactam beta-lactam inhibitors
avibactam and relebactam, and the pleuromutilin antibiotic
lefamulin. These new-in-class anti-infective agents were well
predicted, within a 2-fold difference from the observed EPRs.
Eravacycline was associated with substantial lung penetra-
tion compared to plasma concentrations, with a clinically ob-
served ERP of 6.44, but was miss-classified by the model as
giving under-exposure (EPR<1), indicating that some of the
model predictions should be interpreted with caution for
Table I Overview of Antibiotics and Associated Clinical Studies Included for the External Validation Analysis. All Studies were Conducted in Healthy Volunteers
Except for the Study of Temocillin. Sampling was made with Bronchoalveolar Lavage in ALL Studies Except the Study of Arbekacin and Peramivir for Which
Bronchoscopic Microsampling was Utilized
Drug name Nr of subjects Nr of time
points
Time of last ELF
sample (hours)
Study conducted
at steady state?
Protein binding
(%)
EPR (log EPR) Reference
Arbekacin 6 8 6 - 6 0.72 (-0.33) (6)
Avibactam 42 4 8 + 8 0.35 (-1.05) (7)
Ceftaroline 53 5 12 + 20 0.23 (-1.47) (8)
Ceftolozane 25 5 8 + 20 0.59 (-0.53) (9)
Eravacycline 20 4 12 + 83 6.44 (1.86) (10)
GSK22510052 15 3 12 + 10 0.597 (-0.55) (11)
Imipenem 16 4 3 + 20 0.53 (-0.63) (12)
Lefamulin 12 4 8 - 87 5.7 (1.74) (13)
Omadacycline 42 7 24 + 20 1.84 (0.61) (14)
Peramivir 6 8 5 - 30 (15) 0.54 (-0.61) (16)
Relebactam 16 4 3 + 20 0.54 (-0.61) (12)
Tedizolid 20 4 24 + 89 39.7 (3.68) (17)
Temocillin 10 10 24 + 75 0.57 (-0.56) (18)
Vaborbactam 25 5 8 + 33 0.79 (-0.24) (19)
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compounds that are structurally related to this drug. The
model did however correctly classify all drugs associated with
under-exposure in the ELF compared to plasma. This sug-
gests the clinical applicability of the model as a tool to inform
when dose-adjustments may be warranted and guide in the
adjustment for clinically relevant exposure, which could im-
prove treatment and decrease resistance development.
We were not able to identify clear chemical structure char-
acteristics different from the training set that could explain the
misclassification of eravacycline or the high predictive errors
associated with eravacycline, temocillin, and tedizolid. The
three drugs are all relatively highly bound to plasma proteins
(≥ 75%), which is not currently included in the model.
However, during a post-hoc residual analysis, which included
all drugs present in the validation dataset, no correlation was
found between protein binding and residuals. Antibiotic class,
molecular descriptors, and factors relating to study design
were considered in addition to protein binding. However, no
strong correlations were found in this analysis. Worth consid-
ering is that the ability of detecting correlations was limited
due to the small size of the dataset. In the validation dataset
eravacycline and tedizolid are the only drugs containing fluo-
rine, while in the training dataset all fluorine containing drugs
were primarily fluoroquinolones. Additionally, temocillin was
the only drug studied on patient with lung infections and not
healthy volunteers. Infection could affect the permeability of
the drug to the lungs, i.e. the EPR, contributing to prediction
error. In the original dataset difference in clinical observed
EPR could be seen between diseases states for some of the
drugs. No other study design aspect, such as size of study
cohort or sampling technique, could be linked to the under-
predictions.
We expect that increasing the mechanistic aspects of this
model could improve the model predictions. Currently, plas-
ma protein binding is not explicitly included as a predictor in
the model but potentially its consideration could improve the
predictions. However, the maximal possible quality of this
predictive model is partially limited by the high variability of
the ELF concentrations obtained by BAL sampling. The
method is associated with inherent uncertainty that is partially
related to indirect quantification, possible contamination from
cellular release, and technical errors (3), as well as only
obtaining a single sample per individual. A more novel and
promis ing sampl ing technique i s bronchoscopic
microsampling (BMS), used in 2 of the 14 studies (6,16). The
technique is less invasive than BAL and allows for direct re-
peated measurements of drug concentrations in the ELF over
time (20).
Fig. 1 Log-transformed observed versus predicted lung epithelial lining fluid penetration ratios (EPRs) defined as log(AUCELF/fAUCplasma) stratified by antibiotic
class. The dashed line indicates a 3-fold error.
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CONCLUSION
Although the log EPR predictions by the QSPKR model are
still associated with a significant error, we nonetheless expect
that this QSPKR model is of relevance to determine the ex-
pected magnitude of lung penetration on a semi-quantitative
basis, i.e. under- or over-exposure, or comparable exposure to
plasma. Specifically, the model has relevance to support infor-
mative study design of pharmacokinetic studies (21), potential-
ly in conjunction with population pharmacokinetic models
(22). Future studies to predict the EPR may benefit from a
combined mechanistic PBPK approach to enable prediction
of non-steady state ELF pharmacokinetics, while supported by
a QSPKR model for estimation of the partitioning
coefficients.
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